Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Alimta ® (pemetrexed for injection)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Alimta® (pemetrexed): Prevention and Management of Skin Rash
Skin rash has been reported in patients using pemetrexed not pretreated with a corticosteroid.
Information from Summary of Product Characteristics
Skin reactions have been reported in patients not pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions.1
To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day.1
Management of Pemetrexed Skin Rash
Dose adjustments are recommended in the local labeling if a patient experiences grade 3 or 4 skin toxicity. Treatment may be delayed to allow sufficient time for recovery.2
If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), pemetrexed should be withheld until resolution to less than or equal to the patient’s pre-therapy value.1
Table 1. Dose modification table for pemetrexed (as single agent or in combination) and cisplatin– Non-haematologic toxicities1ab
|
Dose of pemetrexed (mg/m2) |
Dose for cisplatin (mg/m2) |
Any Grade 3 or 4 toxicities except mucositis |
75 % of previous dose |
75 % of previous dose |
a National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998)
b Excluding neurotoxicity
Lilly does not recommend a specific approach to managing pemetrexed-associated rash beyond the guidance provided in the local labeling. Early clinical trial experience noted that the rash typically improved with dexamethasone treatment and resolved upon cessation of pemetrexed therapy.3-5 Current protocols typically allow for the use of supportive care therapies in accordance with local standard practice.2
Prevention of Pemetrexed Skin Rash
Pretreatment with dexamethasone (or equivalent) reduces the incidence and severity of cutaneous reaction. In clinical trials, dexamethasone 4 mg was given by mouth BID the day before, the day of, and the day after pemetrexed administration.2
A small phase 1 study that evaluated 3 different steroid premedication regimens in patients who received pemetrexed for the treatment of advanced HNSCC found that it may be feasible to utilize a 20-mg IV dose of dexamethasone prior to the pemetrexed infusion on the day of treatment in situations in which the patient could not adhere to the oral dexamethasone premedication regimen.2,6
A prospective study evaluated the efficacy of a single IV dose of dexamethasone administered before pemetrexed-based chemotherapy in preventing cutaneous toxicities. Seventy patients with advanced pulmonary adenocarcinoma received either 3 days of oral dexamethasone (4 mg, BID, starting the day before chemotherapy) or a single IV dose of 20 mg dexamethasone prior to pemetrexed. According to the emetogenic potential of the chemotherapy regimen used, 3 to 7 additional doses of oral dexamethasone were given after the administration of chemotherapy in both treatment arms. Patients who received the IV dexamethasone reported 10 episodes of skin rash during the total of 114 chemotherapy cycles (8.9%) while patients who received the standard oral dexamethasone reported 9 episodes of skin rash during the total of 154 cycles (5.8%; p=.35). No grade 3 or 4 skin rash was observed in the whole study population.7
Additional retrospective analyses investigated the preventive effect of dexamethasone on rash development with pemetrexed therapy3,8,9 and alternative regimens of steroid premedication.10-12
1. Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(4):1194. http://dx.doi.org/10.1200/jco.1999.17.4.1194
4. Thödtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999;17(10):3009-3016. http://dx.doi.org/10.1200/JCO.1999.17.10.3009
5. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol. 2002;13(5):737-741. http://dx.doi.org/10.1093/annonc/mdf115
6. Coscio A, William WN Jr, Feng L, et al. Phase I study of pemetrexed in recurrent/metastatic head and neck squamous cell cancer (HNSCC) and to assess the need for steroid premedication [abstract]. J Clin Oncol. 2009;27(suppl 15):e17009. https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.e17009
7. Groleau A, Côté J. Comparison between two premedication regimens of dexamethasone before a pemetrexed-based chemotherapy: a single-center experience study [published online August 1, 2019]. J Oncol Pharm Pract. https://doi.org/10.1177/1078155219862040
8. Usui N, Kondo Y, Okamoto N, et al. Evaluation of the preventive effect of dexamethasone for rash in patients treated with pemetrexed [abstract]. Ann Oncol. 2014;25(suppl 5):v55. https://doi.org/10.1093/annonc/mdu435.49
9. Sakurada T, Kakiuchi S, Tajima S, et al. Pemetrexed-induced rash may be prevented by supplementary corticosteroids. Biol Pharm Bull. 2015;38(11):1752-1756. https://www.jstage.jst.go.jp/article/bpb/38/11/38_b15-00435/_pdf
10. Elsoueidi R, Lander MJ, Richa EM, Adane ED. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions. J Oncol Pharm Pract. 2016;22(2):271-274. https://doi.org/10.1177/1078155215583523
11. Usui N, Kondo Y, Ryota N, et al. Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash. Eur J Hosp Pharm. 2017;24:283-285. https://doi.org/10.1136/ejhpharm-2016-000957
12. Clark SK, Anselmo LM. Incidence of cutaneous reactions with pemetrexed: comparison of patients who received three days of oral dexamethasone twice daily to patients who did not. J Oncol Pharm Pract. 2019;25(7):1645-1650. https://doi.org/10.1177/1078155218804869
Glossary
BID = twice daily
HNSCC = head and neck squamous cell carcinoma
IV = intravenous
Lilly = Eli Lilly and Company
Date of Last Review: 30 August 2019
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays